AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS · Delayed Price · Currency is USD
0.0169
+0.0029 (20.71%)
At close: Jan 23, 2026
AXIM Biotechnologies Revenue
AXIM Biotechnologies had revenue of $17.48K in the quarter ending June 30, 2024, with 76.04% growth. This brings the company's revenue in the last twelve months to $92.90K, up 257.95% year-over-year. In the year 2023, AXIM Biotechnologies had annual revenue of $39.52K with 345.27% growth.
Revenue (ttm)
92.90K
Revenue Growth
+257.95%
P/S Ratio
64.70
Revenue / Employee
13.27K
Employees
7
Market Cap
6.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 39.52K | 30.64K | 345.27% |
| Dec 31, 2022 | 8.88K | -51.59K | -85.32% |
| Dec 31, 2021 | 60.46K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sorrento Therapeutics | 64.27M |
| Carisma Therapeutics | 52.63M |
| Clearside Biomedical | 3.33M |
| Vaccinex | 601.00K |
| Enzolytics | 46.59K |
| Enzon Pharmaceuticals | 26.00K |
AXIM Biotechnologies News
- 1 year ago - VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease - Business Wire
- 2 years ago - AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test - Business Wire
- 2 years ago - Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 2 years ago - AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 2 years ago - AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch - GlobeNewsWire